Compare Alphabet Inc Class A (GOOGL) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Neurocrine Biosciences Inc — how do they compare? Alphabet Inc Class A trades at $351.6 (market cap $4.24T), while Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B). The key difference: Alphabet Inc Class A is far larger — about 295.3× Neurocrine Biosciences Inc's market cap, and Alphabet Inc Class A pays a 0.25% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 85 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GOOGL | NBIX | |
|---|---|---|
Market Cap | $4.24T | $14.36B |
Volume | 23,392,850 | 1,237,180 |
Sector | Media | Health |
52-Week High | $402.62 | $185.50 |
52-Week Low | $236.59 | $123.10 |
Typical Hold Time | 85 Days | 23 Days |
Enterprise Value | $4.13T | $14.37B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $351.66, up 0.33% with strong bullish technical signals from moving averages. The company demonstrates robust fundamentals with revenue growth from $350.0B in 2024 to $402.8B in 2025 and net income surging to $132.2B. Recent earnings beats and a 86.75% analyst buy rating support positive sentiment, while YouTube's subscription price increase and AI partnerships with Anthropic and Intel highlight growth initiatives.
GOOGL presents a compelling investment case with 72 buy ratings and a $431.83 consensus price target offering 23% upside. Strong cash flow generation ($164.7B operating cash flow in 2025) and AI leadership position the stock for continued growth, though antitrust scrutiny and market volatility remain key risks requiring monitoring.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
